This is a working overview of Visceral adiposity, written for readers who want more than a one-paragraph summary but less than a textbook.
Reviewed 2025-11-26. Anything still debated is marked as such rather than presented as settled.
Tesamorelin occupies a narrow position among agents that act on the growth hormone axis. Unlike growth hormone itself, which is given as replacement, it stimulates the pituitary to release the hormone in pulses, so the downstream increase in insulin-like growth factor 1 depends on intact somatotroph function. Other peptides in the same family include shorter GHRH fragments and synthetic secretagogues with different stability profiles. Several points remain unresolved, including whether the reduction in visceral fat translates into fewer cardiovascular events, what happens to metabolic markers after long-term use, and how the drug compares with lifestyle or surgical approaches.
Tesamorelin is a synthetic peptide that belongs to the growth hormone-releasing hormone family and contains the same forty-four amino acid sequence as endogenous GHRH, extended at the amino terminus by a trans-3-hexenoyl group. That small fatty acid modification protects the peptide from rapid cleavage by dipeptidyl peptidase-4, the enzyme that shortens the half-life of native GHRH to only a few minutes. Chemically the compound is produced by solid-phase peptide synthesis, purified by chromatography, and supplied as a sterile lyophilized powder for reconstitution.
Regulatory approval in the United States came in 2010, when the Food and Drug Administration cleared the peptide for the reduction of excess abdominal fat in adults with HIV infection and associated lipodystrophy. The decision rested mainly on two randomized phase 3 trials that enrolled roughly eight hundred patients and ran for twenty-six weeks. Participants receiving active drug showed substantially greater declines in visceral adipose tissue than those receiving placebo, while total body weight changed comparatively little. A reformulated presentation was later approved, and the product has remained a niche therapy rather than a general weight-loss agent.
Stimulated growth hormone release leads to hepatic production of insulin-like growth factor 1, a key mediator of many growth hormone effects. In clinical studies, tesamorelin increased IGF-1 levels in a dose-dependent manner, although the response varies among individuals. The drug's effect on visceral fat is thought to involve growth hormone-mediated lipolysis and altered adipocyte metabolism. Muscle mass and lean body mass have also been assessed as secondary outcomes, but changes are generally smaller and less consistent than fat reductions.
Pharmacodynamic studies show that tesamorelin reduces visceral adipose tissue more than subcutaneous adipose tissue in the studied population. This selectivity may relate to differences in blood flow and hormone sensitivity between fat depots. Effects on glucose metabolism and insulin sensitivity have been investigated, with some trials reporting modest changes and others showing stability. The precise relationship between growth hormone exposure, IGF-1 levels, and visceral fat loss remains an active area of analysis.
| Property | Value | Notes |
|---|---|---|
| Peptide class | Synthetic GHRH analogue | 44 residues; N-terminal trans-3-hexenoyl group |
| First approval year | 2010 | United States; HIV-associated abdominal fat accumulation |
| Administration route | Subcutaneous injection | Abdominal site; clinician-administered or self-injected |
| Common synonyms | TH9507; tesamorelin acetate | Development code and acetate salt form |
| Originator | Canadian biotechnology firm | Original developer and regulatory sponsor |
A documented effect of tesamorelin is a reduction in visceral adipose tissue in some study populations. Researchers have reported decreases in trunk fat measured by computed tomography alongside changes in lipid markers. The mechanism is thought to involve growth hormone-mediated lipolysis, though the precise contribution of direct versus indirect pathways is not fully resolved. Studies have generally examined defined groups over finite periods, so long-term outcomes are less well characterized. Findings have not been uniform across all trials.
Tesamorelin is a synthetic peptide analog of growth hormone-releasing hormone (GHRH). Its sequence corresponds to the 44-amino-acid form of human GHRH with a trans-3-hexenoyl group attached to the N-terminal tyrosine. This modification slows enzymatic cleavage and extends the peptide's activity relative to the native hormone. The compound is produced by solid-phase peptide synthesis and supplied as a lyophilized powder. Researchers classify it as a GHRH receptor agonist. Its structure places it in the same family as other growth hormone secretagogues that act on the pituitary.
Measuring the effect of a growth hormone-releasing hormone analogue requires markers that reflect pituitary output rather than the peptide itself. The two most frequently used are growth hormone and insulin-like growth factor 1. Growth hormone fluctuates sharply across the day and responds to sleep, stress, and meals, so isolated readings can be difficult to interpret. Insulin-like growth factor 1 changes more slowly and is often treated as the more stable integrated marker of axis activity.
Because growth hormone is released in pulses, single measurements can misrepresent overall secretion. Investigators sometimes use repeated sampling or overnight profiles to capture the pattern rather than a single value. Provocative testing, in which a stimulus is given and the response is tracked over time, offers another way to characterize the axis. Each approach carries trade-offs between sensitivity, burden on the participant, and the influence of non-target variables.
=== Computational methods in studying protein biomarkers === One example of the use of bioinformatics and the use of computational methods is the study of protein biomarkers. Computational predictive models have shown that extensive and diverse feto-maternal protein trafficking occurs during pregnancy and can be readily detected non-invasively in maternal whole blood. This computational approach circumvented a major limitation, the abundance of maternal proteins interfering with the detection of fetal proteins, to fetal proteomic analysis of maternal blood. Computational models can use fetal gene transcripts previously identified in maternal whole blood to create a comprehensive proteomic network of the term neonate. Such work shows that the fetal proteins detected in pregnant woman's blood originate from a diverse group of tissues and organs from the developing fetus. The proteomic networks contain many biomarkers that are proxies for development and illustrate the potential clinical application of this technology as a way to monitor normal and abnormal fetal development. An information-theoretic framework has also been introduced for biomarker discovery, integrating biofluid and tissue information. This new approach takes advantage of functional synergy between certain biofluids and tissues with the potential for clinically significant findings not possible if tissues and biofluids were considered individually.
Acrogeria Berardinelli-Seip congenital lipodystrophy (congenital generalized lipodystrophy) Cockayne syndrome Ehlers–Danlos syndromes, progeroid form Gerodermia osteodysplastica Hallermann–Streiff syndrome Mandibuloacral dysplasia Neonatal progeroid syndrome (Wiedemann–Rautenstrauch syndrome) Nestor-Guillermo syndrome Penttinen syndrome Petty–Laxova–Weidemann progeroid syndrome POLR3A-related Wiedemann–Rautenstrauch syndrome PYCR1-related Wiedemann–Rautenstrauch-like syndrome Werner syndrome
=== Medicine === Dozens of congenital metabolic diseases also known as inborn errors of metabolism (IEM) are now detectable by newborn screening tests, especially the testing using gas chromatography–mass spectrometry. GC–MS can determine compounds in urine even in minor concentration. These compounds are normally not present but appear in individuals suffering with metabolic disorders. This is increasingly becoming a common way to diagnose IEM for earlier diagnosis and institution of treatment eventually leading to a better outcome. It is now possible to test a newborn for over 100 genetic metabolic disorders by a urine test at birth based on GC–MS. In combination with isotopic labeling of metabolic compounds, the GC–MS is used for determining metabolic activity. Most applications are based on the use of 13C as the labeling and the measurement of 13C-12C ratios with an isotope ratio mass spectrometer (IRMS); an MS with a detector designed to measure a few select ions and return values as ratios.
== Prognosis == The prognosis for migraine differs from person to person. Often, it improves with age. In women, attacks can stop or diminish after menopause and also during the second and third trimester of pregnancy. A substantial number of people with the condition remain undiagnosed; fewer than half of people with migraine seek medical care. Severe migraine ranks in the highest category of disability, according to the World Health Organization, and the bulk of disability burden is due to chronic (as opposed to episodic) migraine. Repeated experiences of pain, including migraine pain, cause functional and structural changes in the brain. About 2.5% of people with episodic migraines develop chronic migraine each year, while few people with chronic migraine revert back to episodic migraines. People with highly frequent episodic migraines are at high risk in particular. Migraine with aura is associated with an increased risk of ischemic stroke, myocardial infarction, coronary artery disease, and coronary artery dissection (SCAD). This association may reflect shared underlying mechanisms of migraine with aura and cardiovascular disease. Women who experience migraine with aura and use estrogen-containing oral contraceptives have a higher risk of ischemic stroke. In contrast, migraine, generally, and migraine without aura, does not appear to be related to increased risk of stroke or heart disease. Preventive therapy, particularly for those with migraine with aura, may prevent associated strokes.
Sources: en.wikipedia.org
=== BLAST networking technology === Networks based on DASH7 differ from typical wire-line and wireless networks utilizing a "session". DASH7 networks serve applications in which low power usage is essential and data transmission is typically much slower and/or sporadic, like basic telemetry. Thus, instead of replicating a wire-line "session", DASH7 was designed with the concept of B.L.A.S.T.:
The Six Million Dollar Man is an American science fiction and action television series, running from 1973 to 1978, about a former astronaut, USAF Colonel Steve Austin, portrayed by Lee Majors. After being seriously injured in a NASA test flight crash, Austin is rebuilt (at considerable expense, hence the title of the series) with bionic implants that give him superhuman strength, speed and vision. Austin is then employed as a secret agent by a fictional American government office titled OSI. The series was based on Martin Caidin's 1972 novel Cyborg, which was the working title of the series during pre-production. Following three television films intended as pilots, which all aired in 1973, The Six Million Dollar Man television series aired on the ABC network as a regular episodic series for five seasons from 1974 to 1978. Steve Austin became a pop culture icon of the 1970s.
== Procedure == Sperm washing takes place in a laboratory following sperm donation. Sperm may be washed by density gradient centrifugation or by a "direct swim-up" technique that does not involve centrifugation. In normal semen samples, centrifugation causes no more DNA damage to spermatozoa than a direct swim-up technique. Washed sperm is concentrated in Ham's F-10 media without L-glutamine, warmed to 37 °C (99 °F). A chemical known as a cryoprotectant is added to the sperm to aid the freezing and thawing process. Further chemicals may be added which separate the most active sperm in the sample, as well as extend or dilute the sample so that vials for a number of inseminations are produced.
== American Chemical Society == The Frank H. Field and Joe L. Franklin Award for Outstanding Achievement in Mass Spectrometry is the major mass spectrometry award offered by the American Chemical Society.
==== International Congress of Refrigeration ==== First held in 1908, the International Congress of Refrigeration of the IIR is a flagship event that converges industry and research. Covering all fields of refrigeration, the Congress, which takes place every four years, reunites key international stakeholders and provides perspectives on the future of the industry in line with sustainable development.
Sources: en.wikipedia.org
=== Operation Enduring Freedom – Horn of Africa === During December 2002 and January 2003, Special Operation Detachment – Central (SOD-C) arrived to augment Joint Special Operations Task Force – Horn of Africa (JSOTF-HOA). The SOD concept was new and consisted of experienced National Guard Special Forces Officers and NCOs who served as the JSOTF's core staff. Besides the SOD-C, JSOTF-HOA included Air Force Special Operations Detachment-Alpha (AFSOD-A), an SF detachment, a SEAL platoon, and a Naval Special Warfare (NSW) rigid inflatable boat (RIB) detachment. In November 2006, 20th SFG Headquarters deployed to round out the Special Operations Command and Control Element – Horn of Africa (SOCCE-HOA) staff for two years. This initiative allowed SOCCE-HOA to better accomplish its missions. American Special Forces carried out operations in support of Ethiopian troops during the invasion of Somalia in December 2006 aimed at toppling the Islamic Courts Union.
David Giorgio Mendes Nassi (Hebrew: דוד ג'ורג'יו מנדס) is an Israeli orthopedic surgeon who has developed advanced methodologies and systems in the area of Hip and Knee artificial joint replacement. .
=== Metropolis-coupled MCMC === Metropolis-coupled MCMC algorithm (MC³) has been proposed to solve a practical concern of the Markov chain moving across peaks when the target distribution has multiple local peaks, separated by low valleys, are known to exist in the tree space. This is the case during heuristic tree search under maximum parsimony (MP), maximum likelihood (ML), and minimum evolution (ME) criteria, and the same can be expected for stochastic tree search using MCMC. This problem will result in samples not approximating correctly to the posterior density. The (MC³) improves the mixing of Markov chains in presence of multiple local peaks in the posterior density. It runs multiple (m) chains in parallel, each for n iterations and with different stationary distributions
CT is the total inorganic carbon [CO2*] is the sum of carbon dioxide and carbonic acid concentrations ([CO2*] = [CO2] + [H2CO3]) [HCO−3] is the bicarbonate concentration [CO2−3] is the carbonate concentration Each of these species are related by the following pH-driven chemical equilibria:
Sources: en.wikipedia.org
It is a laboratory-made peptide of forty-four amino acids whose sequence matches human growth hormone-releasing hormone, with a modified amino terminus. The modification is a short unsaturated fatty acid chain attached to the first residue. This change slows enzymatic breakdown and lengthens the time the peptide stays active in circulation.
The clinical program was designed around HIV-associated lipodystrophy, a condition in which fat accumulates abnormally around the internal organs. Trials enrolled that specific population, so the evidence base covers it rather than the general population. Regulators approved the drug for the studied indication only, and promotion outside it is not permitted.
Growth hormone therapy supplies the finished hormone directly, while this peptide acts upstream and asks the pituitary to secrete its own. That difference means the response depends on a functioning pituitary and on the body's normal feedback loops. It also means the circulating hormone profile is pulsatile rather than a flat, injected level.
It targets the growth hormone-releasing hormone receptor on pituitary somatotroph cells. Binding stimulates cyclic AMP signaling and growth hormone secretion. This is the same receptor used by endogenous GHRH.